Solence
Solence: Digital medical device helping women understand and manage PCOS symptoms through personalized daily routines. HealthTech · Seed · Paris, France.…
Digital medical device helping women understand and manage PCOS symptoms through personalized daily routines.
Preliminary profile · public data only
Startup24 listed Solence from public information on the company's own website; its founders have not claimed or verified the profile yet. The rating below is preliminary, based on public data only, and is an opinion — not investment advice. Founders can claim the profile, and anyone can report an error or request removal, on this page.
At a glance
- Category: HealthTech (Women's digital health and PCOS management)
- Stage: Seed
- Location: Paris, France
Startup24 rating: 61/100
Solence targets a large, underserved PCOS population with a regulated product that is relatively mature for seed stage, supported by scientific involvement and reported early funding. The opportunity is promising, but product impact, paid demand and scalable distribution remain unverified. Sparse team disclosure and missing revenue, burn and runway data also limit confidence in execution and financial resilience. Publishing evidence and clarifying team capacity and financials would strengthen investor readiness.
- Team: 48/100
- Market: 72/100
- Product: 71/100
- Advantages: 63/100
- Risk: 52/100
- Reputation: 60/100
About the rating
Every startup on Startup24 is scored on the same six criteria — team, market, product, advantages, risk and reputation — with the reasoning written out. Founders list for free; investors subscribe to see the full analysis.
Startup24 (startup-24.com) rates startups on real, verified data: founders list for free, investors subscribe to find them first. Operated by DOTOVO OÜ, Tallinn, Estonia.